Comprehensive Care Medicine Precautions Dental Care Immunizations Joint Bleeds Mouth Bleeds Nose Bleeds

Head Injuries The Pain Trajectory Starting an Exercise Program Physical Activity Safety Knowledge Base

 

Knowledge Base

Knowledge, Attitudes, and Behaviors of Youths in the US Hemophilia Population: Results of a National Survey.
Ann-Marie Nazzaro, PhD, Sally Owens, BSN, W. Keith Hoots, MD and Kelly L. Larson, MPH
www.ajph.org/cgi/content/abstract/96/9/1618

Issues surrounding therapeutic choices for hemophilia patients.
haematologica 2004; 89(6):June 2004
www.haematologica.it/cgi/reprint/89/6/645

Congenital Hemorrhagic Disorders: New Insights into the Pathophysiology and Treatment of Hemophilia.
Ulla Hedner, (Chair), David Ginsburg, Jeanne M. Lusher and Katherine A. High
Hematology 2000
asheducationbook.hematologylibrary.org/cgi/reprint/2000/1/241

Hemophilia, Overview

Author: Dimitrios P Agaliotis, MD, PhD, FACP, Consulting Staff, Department of Medicine, Baptist Health System
www.emedicine.com/med/topic3528.htm

Economics of prophylactic treatment
W. Schramm and K. Berger
University Hospital of Munich, Department of Haemostasis and Transfusion Medicine, Ziemssenstrasse 1, 80336 Munich, Germany
Haemophilia (2003), 9, (Suppl. 1), 111–116

Home management of haemophilia
J. M. Teitel
Haemophilia (2004), 10, 118–133
www.medscape.com/medline/abstract/14962201

Continuous Infusion

Factor Replacement by Continuous Infusion, 3rd Edition. February 2004.
Donna M. M. Woloschuk, Pharm D., Nora Schwetz, R.N., B.Sc.
www.hsc.mb.ca/cifr/media/CIFR_Guide_3rd_Edition_English.pdf

Inhibitors

Public statement: EMEA completes the review of recombinant factor VIII products1 and
inhibitor development. European Medicines Agency Post-Authorisation Evaluation of Medicines for Human Use. July 31, 2007.
www.emea.europa.eu/pdfs/human/press/pus/31022507en.pdf

Recombinant versus plasma-derived factor VIII products and the development
of inhibitors in previously untreated patients with severe hemophilia A:
the CANALcohort study
Samantha C. Gouw et al. for the CANAL Study group. Blood, 1 June 2007. Volume 109, Number 11.
bloodjournal.hematologylibrary.org/cgi/reprint/109/11/4693

Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group.
Alessandro Gringeri, Lorenzo G. Mantovani, Luciana Scalone, and Pier Mannuccio Mannucci, for the COCIS Study Group.
Blood, 1 October 2003, Volume 102, Number 7
www.eschqol.lmu.de/downloads/Gringeri1.pdf

Acquired Inhibitors

Acquired Factor VIII Inhibitors: Pathophysiology and Treatment.
Alice D. Ma and Daniel Carrizosa. Hematology 2006.
http://asheducationbook.hematologylibrary.org/cgi/content/full/2006/1/432

http://www.emedicine.com/med/topic3779.htm

Costs

The economics of bleeding disorders. R. L. BOHN. Haemophilia (2000), 6, 491-493.